Immunic IMU-856 trial data "clearly goes beyond" initial expectations

May 04, 2023 at 08:23 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at restoring healthy gut function.

The molecule has shown promise in treating celiac disease, with potential applications for other gastrointestinal disorders such as Crohn's disease and ulcerative colitis. Immunic Inc. plans to conduct a Phase 2 clinical trial for IMU-856 in celiac disease patients and explore other potential applications, saying that the phase 1b results "clearly go beyond" initial expectations.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	246.03	-7.76 (-3.06%)
AAPL	307.34	-3.89 (-1.25%)
AMD	466.38	-56.82 (-10.86%)
BAC	53.83	-0.06 (-0.11%)
GOOG	365.76	-3.51 (-0.95%)
META	593.00	-34.57 (-5.51%)
MSFT	416.67	-11.38 (-2.66%)
NVDA	205.10	-13.56 (-6.20%)
ORCL	213.68	-22.66 (-9.59%)
TSLA	391.00	-27.45 (-6.56%)

Symbol

Price

Change (%)

AMZN

246.03

-7.76 (-3.06%)

AAPL

307.34

-3.89 (-1.25%)

AMD

466.38

-56.82 (-10.86%)

BAC

53.83

-0.06 (-0.11%)

GOOG

365.76

-3.51 (-0.95%)

Immunic IMU-856 trial data "clearly goes beyond" initial expectations

Contact Details

More News

Recent Quotes